Recent News for DTIL - Precision BioSciences, Inc.

Date Title
Apr 15 Precision BioSciences appoints new CMO
Apr 15 Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer
Apr 15 Precision Biosciences reacquires global rights to allogeneic CAR T programs
Apr 15 Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs
Apr 12 Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors
Apr 9 Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series
Apr 6 Precision BioSciences announces CEO transition plan
Apr 6 Precision BioSciences Announces CEO Transition Plan
Mar 29 Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day
Mar 25 The Prognosis For Precision BioSciences
Mar 18 ROCE Insights For Precision BioSciences
Mar 18 Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates
Mar 18 Recap: Precision BioSciences Q4 Earnings
Mar 18 Earnings Scheduled For March 18, 2021
Mar 18 Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
Mar 14 Precision BioSciences: New Gene Editing Company With Major Deals
Mar 12 Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021
Mar 2 Will Precision BioSciences (DTIL) Report Negative Q4 Earnings? What You Should Know
Mar 2 Precision BioSciences to Present at Upcoming Virtual Investor Conferences
Feb 19 Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows
Feb 19 Precision Bio announces peer-reviewed data supporting gene editing platform
Feb 19 The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko
Feb 19 Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates
Feb 11 Precision BioSciences (NASDAQ:DTIL) Shareholders Have Enjoyed A 64% Share Price Gain
Feb 4 Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day
Back to the Main DTIL Page...